Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mastewal Abuhay"'
Autor:
Emily Tuscano, Gustavo A. Barisone, Mastewal Abuhay, Jason Kato, Robert T. O'Donnell, Ranjit S. Sidhu, Joseph Tuscano
Publikováno v:
Cancer immunology, immunotherapy : CII, vol 65, iss 10
Cancer Immunol Immunother
Cancer Immunol Immunother
In this study, the HB22.7 anti-CD22 mAb, was used for specific, targeted delivery of the potent anti-cancer agent, monomethyl auristatin E (MMAE) to non-Hodgkin lymphoma (NHL). MMAE was covalently coupled to HB22.7 through a valine-citrulline peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0851ce34208080ebdc9b78773ef13fe
https://doi.org/10.1007/s00262-016-1873-y
https://doi.org/10.1007/s00262-016-1873-y
Autor:
Mastewal Abuhay, Sonia Gowda, Kathleen Lundeberg, Gustavo A. Barisone, Joseph Tuscano, Robert T. O'Donnell, Yunpeng Ma
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 1, p e0190860 (2018)
PLoS ONE, Vol 13, Iss 1, p e0190860 (2018)
Non-Hodgkin lymphoma (NHL) affects over 400,000 people in the United States; its incidence increases with age. Treatment options are numerous and expanding, yet efficacy is often limited by toxicity, particularly in the elderly. Nearly 70% patients e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d98e94739640ce54e812ff1e4ed1d1
http://europepmc.org/articles/PMC5755921
http://europepmc.org/articles/PMC5755921
Publikováno v:
Leukemia Research. 37:83-88
Targeted therapies, such as those using imatinib and rituximab, have revolutionized the treatment of Philadelphia chromosome-positive and CD20-positive acute lymphoblastic leukemia (ALL) respectively, yet these therapies are effective in only a subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5094017acaa033593281ed54000601e6
https://doi.org/10.1016/j.leukres.2012.09.010
https://doi.org/10.1016/j.leukres.2012.09.010
Autor:
Gustavo A. Barisone, YanGuo Kong, Zaneb Buksh, Joseph Tuscano, Mastewal Abuhay, Robert T. O'Donnell, Faraz Yousefian
Publikováno v:
Leukemia research. 38(11)
HB22.7, an anti-CD22 monoclonal antibody has shown consistent preclinical activity against non-Hodgkin lymphoma (NHL). Histone deacetylase inhibitors (HDACi) have demonstrated efficacy in lymphoma and can modulate cell surface receptor expression. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0badefa56461aa6d2676f7a22f838933
https://pubmed.ncbi.nlm.nih.gov/25241275
https://pubmed.ncbi.nlm.nih.gov/25241275
Publikováno v:
Oncoimmunology
Oncoimmunology, vol 1, iss 9
Oncoimmunology, vol 1, iss 9
Antibody drug conjugates (ADCs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal antibodies (mAbs). ADCs have demonstrated significant anticancer activity and, in 2011, brentuximab vedotin has been approved by the F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7632c077736bea63b7ea6abaeda1df6
https://pubmed.ncbi.nlm.nih.gov/23264893
https://pubmed.ncbi.nlm.nih.gov/23264893
Publikováno v:
The Journal of Immunology. 192:203.12-203.12
The immune system is an essential defense against malignancy; immunosuppression increases the risk of developing cancer. A better understanding of how to modulate the immune system may lead to new methods to prevent and treat disease. While recent de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba13c02c5cd42aec0be1007551e7b560
https://doi.org/10.4049/jimmunol.192.supp.203.12
https://doi.org/10.4049/jimmunol.192.supp.203.12